| Biomarker ID | 506 |
| PMID | 20035634 |
| Year | 2009 |
| Biomarker | PDIA3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Gleason Score 8-10 |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-N-glycan trimming in the ER and calnexin/calreticulin cycle, Antigen processing: cross presentation, Antigen processing and presentation, Asparagine N-linked glycosylation, Protein processing in the endoplasmic reticulum |
| Experiment | Gleason Score 6 Vs Gleason Score (8-10) |
| Type of Biomarker | Prognostic |
| Cohort | 65 RNA samples derived from 13 benign and 52 prostate cancer tissue comprising 25 samples with Gleason Score (GS) 6 and 27 samples with GS 8-10 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | qRT-PCR: p=0.00167 |
| Method Used | qRT-PCR and Immunohistochemistry |
| Clinical | No |
| Remarks | Another 2500 differentially expressed genes between prostate cancer and benign samples are available from supplementry material of the paper |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PDIA3 |